肾移植受者的膳食锂摄入量与移植物衰竭及死亡率的关系
在642例稳定肾移植受者中测量尿锂排泄量以反映膳食锂摄入,中位随访5.3年间79例(12%)发生移植物衰竭、127例(20%)发生肾功能下降。尿锂排泄量每翻倍与移植物衰竭风险降低相关(HR 0.54,95%CI 0.38-0.79),与肾功能下降风险降低相关(HR 0.73,95%CI 0.54-0.99),并与全因死亡风险降低相关(HR 0.64,95%CI 0.49-0.83)。
要点
- 尿锂排泄量每翻倍,移植物衰竭风险HR 0.54(95%CI 0.38-0.79)。
- 尿锂排泄量每翻倍,肾功能下降风险HR 0.73(95%CI 0.54-0.99)。
- 尿锂排泄量每翻倍,全因死亡风险HR 0.64(95%CI 0.49-0.83),P=.001。
核心结论
- 膳食锂摄入可能是肾移植受者长期移植物不良结局和患者生存的潜在可改变但被忽视的风险因素。
研究设计与样本
- 在642例稳定肾移植受者中,采用电感耦合等离子体质谱法测定尿锂浓度,以反映膳食锂摄入。
- 移植物衰竭定义为开始透析或再次移植,肾功能下降定义为血清肌酐翻倍。
- 中位随访5.3年(IQR 4.5-6.0)。
主要发现
- 尿锂排泄量中位数为3.03 μmol/24 h(IQR 2.31-4.01),与能量、植物蛋白和水的摄入量相关。
- 随访期间79例(12%)发生移植物衰竭,127例(20%)发生肾功能下降。
- 尿锂排泄量较高与移植物衰竭风险较低相关,HR每翻倍0.54(95%CI 0.38-0.79)。
- 尿锂排泄量较高与肾功能下降风险较低相关,HR每翻倍0.73(95%CI 0.54-0.99)。
- 尿锂排泄量较高与全因死亡风险降低相关,HR 0.64(95%CI 0.49-0.83),P=.001。
关键数值与推荐
- 尿锂排泄量较高与移植物衰竭风险较低相关,HR每翻倍0.54(95%CI 0.38-0.79)。
- 尿锂排泄量较高与肾功能下降风险较低相关,HR每翻倍0.73(95%CI 0.54-0.99)。
- 尿锂排泄量较高与全因死亡风险降低相关,HR 0.64(95%CI 0.49-0.83),P=.001。
- 使用增殖抑制剂(P=.05)和基线eGFR(P<.001)存在显著效应修饰,在不使用增殖抑制剂和基线eGFR较低的受者中尿锂排泄量较高的保护作用更强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term high-dose lithium therapy in bipolar disorder is known to adversely affect kidney function. However, recent animal studies have revealed that low amounts of lithium are beneficial for the kidney when it is damaged by exposure to nephrotoxic compounds, inflammation or oxidative stress. This study aimed to investigate whether urinary lithium excretion, reflecting dietary lithium intake, is associated with adverse long-term kidney graft outcomes and patient survival. METHODS: Urinary lithium concentration was measured using inductively coupled plasma mass spectrometry in 642 stable kidney transplant recipients (KTRs). Graft failure was defined as the start of dialysis or retransplantation and kidney function decline was defined as a doubling of serum creatinine. RESULTS: The median urinary lithium excretion was 3.03 μmol/24 h [interquartile range (IQR) 2.31-4.01]. Urinary lithium excretion was associated with energy, plant protein and water intake. During a median follow-up of 5.3 years (IQR 4.5-6.0), 79 (12%) KTRs developed graft failure and 127 (20%) KTRs developed kidney function decline. Higher urinary lithium excretion was associated with a lower risk of graft failure {hazard ratio [HR] per doubling 0.54 [95% confidence interval (CI) 0.38-0.79]} and kidney function decline [HR per doubling 0.73 (95% CI 0.54-0.99)]. These associations remained independent of adjustment for potential confounders and in sensitivity analyses. There was a significant effect modification with the use of proliferation inhibitors (P = .05) and baseline estimated glomerular filtration rate (eGFR; P < .001), with higher urinary lithium excretion being more protective in KTRs not using proliferation inhibitors and in KTRs with lower baseline eGFR. Furthermore, higher urinary lithium excretion was associated with a reduced risk of all-cause mortality [HR 0.64 (95% CI 0.49-0.83); P = .001]. CONCLUSION: Dietary lithium intake may be a potentially modifiable, yet rather overlooked, risk factor for adverse long-term kidney graft outcomes and patient survival. TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT02811835.
引用
- Post A, Kremer D, Groothof D, et al. Dietary lithium intake, graft failure and mortality in kidney transplant recipients. Nephrol Dial Transplant. 2023. PMID: 36564033. doi:10.1093/ndt/gfac340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。